Alnylam initiates rolling submission of nda for lumasiran for the treatment of ph1

Alnylam initiates rolling submission of new drug application (nda) to u.s. food and drug administration (fda) for lumasiran for the treatment of primary hyperoxaluria type 1 (ph1).alnylam initiates rolling submission of new drug application (nda) to u.s. food and drug administration (fda) for lumasiran for the treatment of primary hyperoxaluria type 1 (ph1).alnylam pharmaceuticals inc - company plans to complete submission in early 2020.alnylam pharmaceuticals inc - lumasiran granted pediatric rare disease designation by fda for treatment of ph1.alnylam pharmaceuticals inc - intends to file a marketing authorisation application with ema in early 2020.
ALNY Ratings Summary
ALNY Quant Ranking